Foghorn Therapeutics Inc.

We're looking forward to the upcoming B. Riley Securities Precision Oncology and Radiopharma Conference and the TD Securities 45th Annual Health Care Conference. Join us for a panel discussion and presentation as we share insights on our pioneering work to modulate the chromatin regulatory system. Learn more: https://bit.ly/41hGCTE

We’re looking forward to presenting at the upcoming Keystone Symposia on Molecular & Cellular Biology. If you’re attending, be sure to catch Foghorn’s presentations on our pioneering approach to modulating the chromatin regulatory system and hear about the significant progress we’ve made. Check out the agenda to learn more: https://lnkd.in/gNKHp98f

Today, on International Day of Women and Girls in Science, we celebrate the incredible women at Foghorn who are driving innovation and pushing the boundaries of discovery. From the lab to the clinic, their contributions are shaping the future of science and medicine, and we’re thankful for their dedication to transform the lives of people across a wide spectrum of diseases. #WomeninSTEM #IDWGS #February11

Last month, the Foghorn team welcomed 2025 in style at our annual holiday party & awards ceremony! From festive decorations to shared laughter and great company, it was the perfect way to wrap up an incredible 2024 and toast to the year ahead. We’re so grateful for this team and the memories we’re making—here’s to all that’s to come in 2025!

Did you catch Foghorn CEO Adrian Gottschalk's interview at the Flagship Pioneering studio during #JPM25? Adrian shares insights into our pioneering work with the chromatin regulatory system, pipeline progress, and what’s ahead in 2025. Watch the full video: https://bit.ly/4jJnp67 #FlagshipFounded

As we kick off 2025, we’re pleased to share our strategic objectives for the year and the significant progress made across our programs. With a robust balance sheet and an advancing pipeline, we are poised for an impactful year to advance programs with the potential to transform cancer treatment. Discover more about our progress and what’s ahead in 2025: https://bit.ly/4heMSlQ

Our Foghorn team had a blast celebrating the season with some fun surprises at our annual Yankee Swap! Wishing everyone a joyful and healthy holiday season from all of us at Foghorn.

Join us at the Cell Press’s Chemical Biology in Drugging the Undrugged Symposia to hear the Head of our Protein Degrader Platform, Danette Daniels, give an oral presentation about our pioneering work to create medicines that are designed to modulate the chromatin regulatory system. See the agenda and learn more: https://bit.ly/3B93POU

Today, we’re especially grateful for our Foghorn team who are dedicated to our mission to transform the lives of people across a wide spectrum of diseases. Happy Thanksgiving, everyone!

In a recent interview with Adil Ali, MD, at Onyx, our CEO, Adrian Gottschalk, shared his perspective on the biotech industry and gave an inside look at Foghorn’s pioneering work in the chromatin regulatory system. The feature spotlights our innovative approach and a key milestone: dosing the first patient in our Phase 1 trial of FHD-909 (LY4050784), a selective SMARCA2 inhibitor developed in collaboration with Eli Lilly. Discover more about our science, and the journey that brought Adrian to Foghorn: https://bit.ly/4980BaW